MedPath

A study to compare the effect of blood component and dextrose injection in patients of chronic severe plantar fasciitis

Phase 2/3
Not yet recruiting
Conditions
Plantar fasciitis
Registration Number
CTRI/2018/02/012220
Lead Sponsor
Krishna B
Brief Summary

Plantar fasciitis is the most common cause of inferior heel pain affecting 10-15% of general population at least once in their lifetime. Studies have shown that roughly 10 percent of plantar fasciitis patients are nonresponders to conservative treatment.

Surgical correction of plantar fasciitis involves open/percutaneous or endoscopic plantar fascia release which is associated with increased stress on ligaments of forefoot and midfoot resulting in further complications. This creates a window for injection therapies in non-responders to conservative management. Commonly used local steroid injection has been associated with atrophy of plantar fascia, subcutaneous fat and even plantar fascia rupture. Moreover, steroids are generally indicated in acute, not chronic cases, which is the focus of this study.

On the other hand, prolotherapy with dextrose (DP) has been reported to decrease pain and improve function in a variety of tendinopathies, by upregulating multiple mitogenic factors. And, complete resolution of symptoms at one year was reported in 75% of subjects with plantar fasciitis treated with PRP by Barrett SL et al.

But, no trial has directly compared the effectiveness of dextrose prolotherapy with PRP in chronic plantar fasciitis in Indian population. Nor have any studies compared change in ultrasound parameters, as an outcome measure between PRP and DP in chronic plantar fasciitis.

Detailed Description

Not available

Recruitment & Eligibility

Status
Not Yet Recruiting
Sex
All
Target Recruitment
60
Inclusion Criteria
  • Patient diagnosed with unilateral or bilateral plantar fasciitis having no improvement with conservative management for ≥ 3 weeks.
  • 2.Physical examination revealing maximum tenderness at the attachment of plantar fascia on the medial tubercle of the calcaneus.
  • 3.Ultrasound examination showing plantar fascia thickness ≥4 mm or difference in plantar fascia thickness ≥1 mm in symptomatic heel in comparison to asymptomatic heel at inferior border of the calcaneus.
  • 4.In bilateral cases, foot with more clinical severity is taken into the study.
Exclusion Criteria
  • 1.Received local steroid injection within 6 months 2.
  • NSAID use 7 days prior to randomization 3.
  • History of anaemia or bleeding disorders 4.
  • Previous surgery for plantar fasciitis 5.
  • Achilles tendon pathology 6.Diagnosed case of local malignancy 7.Diagnosed case of rheumatological diseases 8.Uncontrolled diabetes mellitus 9.Patients on anticoagulation therapy 10.
  • Diagnosis of vascular insufficiency or neuropathy related heel pain (radiculopathy, tarsal tunnel syndrome) and other causes of heel pain 11.
  • Any local trauma or infection.
  • 12.Not willing to participate in study.

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Change in sonographic appearance of the plantar fascia, with respect to thickness and presence or absence of hypoechogenic foci0 weeks , 4 weeks, 8 weeks
Secondary Outcome Measures
NameTimeMethod
Change in functional outcome assessed by Foot Function Index0 weeks, 4 weeks, 8 weeks
Change in symptom severity assessed by Foot Function Index0 weeks, 4 weeks, 8weeks

Trial Locations

Locations (1)

AIIMS

🇮🇳

South, DELHI, India

AIIMS
🇮🇳South, DELHI, India
Krishna B
Principal investigator
8122981744
beekrishna@gmail.com

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.